WELCOME TO The Biotechnology REPORT
Health Resources International Ltd
Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...
Labiotech | February 06, 2020
Camena Bioscience has achieved a significant DNA synthesis milestone by reproducing the DNA sequence of a whole plasmid, which could be used in synthetic biology applications such as protein production and bacterial engineering. DNA synthesis is a field that, until recently, had not been a focus for companies developing innovative technologies, with greater importance being placed on DNA sequencing and manipulation tools....
Texas Children's Hospital | May 09, 2022
Texas Children's Physician Group announced today that it has completed the acquisition of Austin Perinatal Associates, a well-known private maternal-fetal medicine practice based in Austin.
Located at 6500 North Mopac Expressway, the facility is the ninth community maternal-fetal medicine clinic operated by the Texas Children's Pavilion for Women and the first to offer women's services in Central Texas – bringing the hospital's well-known, top tier women'...
CELL AND GENE THERAPY
PerkinElmer | September 18, 2021
PerkinElmer, Inc.a global leader committed to innovating for a healthier world, today announced it has completed its acquisition of BioLegend, a leading, worldwide provider of life science antibodies and reagents for a total consideration of approximately $5.25 billion.
The acquisition, the largest in PerkinElmer’s history, further expands the Company’s life science franchise into high-growth areas such as cytometry, proteogenomics, multiplex assays, recombinant protei...
Diverse Biotech | May 04, 2020
Diverse Biotech, Inc. www.diversebiotech.com has announced the U.S. Food & Drug Administration (FDA) has granted an orphan-drug designation request for one of its investigational new therapies for treatment of newly diagnosed glioblastoma, in conjunction with standard treatment, following adjuvant combined chemo-radiation. Orphan designation qualifies the sponsor of the drug for various development incentives of the ODA, (Orphan Drug Act) including tax credits for qualified clinical te...
Keep me plugged in with the best
Join thousands of your peers and receive our weekly newsletter with the latest news, industry events, customer insights, and market intelligence.
Put your news, events, company, and promotional content in front of thousands of your peers and potential customers.
Not a member yet? Not a problem, Sign Up
Sign up to contribute and publish your news, events, brand, and content with the community for FREE